Company Filing History:
1 out of 495 
1 out of 258 Years Active: 2022
Title: Jarrett Adams: Innovator in CD133-Binding Agents
Introduction
Jarrett Adams is a notable inventor based in Toronto, Canada. He has made significant contributions to the field of biomedical research, particularly in the development of novel CD133-binding agents. His work focuses on the detection and quantification of CD133-expressing cells, which are crucial in cancer research and treatment.
Latest Patents
Jarrett Adams holds a patent for "CD133-binding agents and uses thereof." This patent is directed towards innovative agents that bind to CD133, enabling the detection of CD133-expressing cells. The applications of these agents include targeting CD133-expressing cells, decreasing CD133 levels in these cells, and providing potential treatments for cancer. He has 1 patent to his name.
Career Highlights
Throughout his career, Jarrett has worked with prestigious institutions such as the University of Toronto and McMaster University. His research has contributed to advancements in understanding cellular mechanisms related to cancer.
Collaborations
Jarrett has collaborated with esteemed colleagues, including Jason Moffat and Guohua Pan. Their combined expertise has furthered research in the field of cancer treatment and cellular biology.
Conclusion
Jarrett Adams is a pioneering inventor whose work on CD133-binding agents has the potential to impact cancer research significantly. His contributions to the field highlight the importance of innovation in medical science.